Table 1.
Demographic and clinical profile.
| SARS-CoV-2 positive population (n = 6630) | |
|---|---|
| Age, median (range) (years) | 17.6 (15–20) |
| Sex, n (%) | |
| Female, n (%) | 3873 (58.4) |
| Male, n (%) | 2757 (41.6) |
| Body Mass Index (BMI)a | |
| Underweight, n (%) | 121 (1.8) |
| Normal weight, n (%) | 5312 (80.2) |
| Overweight, n (%) | 866 (13.1) |
| Obesity, n (%) | 325 (4.9) |
| Pre-existing co-morbidityb | |
| Asthma, n (%) | 507 (7.7) |
| Allergy, n (%) | 1248 (18.8) |
| Eczema, n (%) | 371 (5.6) |
| Tics, n (%) | 66 (1.0) |
| Lyme's disease, n (%) | <5 (0.03) |
| ADHD/ADS, n (%) | 176 (2.7) |
| Epstein-Barr Virus, n (%) | 166 (1.8) |
| Arthritis, n (%) | 26 (0.4) |
| ME/CFC, n (%) | 23 (0.4) |
| Autism, n (%) | 108 (1.6) |
| Urticaria, n (%) | <5 (0.1) |
| Dyspraxia, n (%) | <5 (0.02) |
| Hyper-mobility, n (%) | 124 (1.9) |
| HPV virus, n (%) | 5 (0.1) |
| OCD/anxiety/depression, n (%) | 365 (5.5) |
| Hyperthyroidism, n (%) | <5 (0.03) |
| Hypertonia, n (%) | <5 (0.1) |
| Other, n (%) | 177 (2.7) |
| Self-reported severity of COVID-19 | |
| No symptoms, n (%) | 2241 (33.8) |
| Mild symptom burden, n (%) | 3795 (57.2) |
| Severe symptom burden, n (%) | 594 (9.0) |
| Duration of acute COVID symptoms | |
| 1–3 days, n (%) | 794 (18.1) |
| 4–6 days, n (%) | 1236 (28.2) |
| 7–10 days, n (%) | 969 (22.1) |
| 11–14 days, n (%) | 512 (11.7) |
| More than 14 days, n (%) | 878 (20.0) |
SD= standard deviation, ADHD/ADS=Attention deficit hyperactivity disorder/Attention deficit syndrome, ME/CFC=Myalgic encephalomyelitis/Chronic fatigue syndrome, OCD=Obsessive-compulsive disorder.
a
6 participants had missing information on BMI.
b
Participants were asked about co-morbidity before COVID-19 infection.